SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Merck discontinues Phase 3 BELLWAVE-011 trial after EDMC review

MRK

Story updates

09:16:30 PM UTC
SquawkNews
Merck halts nemtabrutinib development after trial review flags unfavorable risk-benefit profile

Related stories